Peng Xie1, Minghuan Li, Hanxi Zhao, Xindong Sun, Zheng Fu, Jinming Yu. 1. Department of Radiation Oncology, Shandong Tumor Hospital and Institute, Key Laboratory of Radiation Oncology of Shandong Province, Jiyan Road 440, 250117, Jinan, Shandong Province, China.
Abstract
PURPOSE: The purpose of this meta-analysis was to evaluate the prognostic value of standard uptake value (SUV) from serial Fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography ((18)F-FDG PET/CT) in patients with head and neck cancer. METHODS: We searched for articles limited to head and neck cancer, dealt with the impact of SUV on survival and published in English. The endpoints were disease-free survival (DFS), overall survival (OS), and local control (LC). Two reviewers extracted data independently. RESULTS: Thirty-five studies were identified; of which, 26 studies involving 1,415 patients met the inclusion criteria. Pooled survival data suggested better DFS, OS, and LC in patients with low SUV of pre-treatment, and the odds ratio (OR) was 0.23, 0.24, and 0.27, respectively. Patients having tumors with low SUV of post-treatment also had significantly better DFS (OR = 0.17) and OS (OR = 0.28) than those with high SUV. CONCLUSIONS: The present meta-analysis showed that (18)F-FDG uptake, as measured by the SUV before treatment and metabolic response after treatment, are valuable for predicting long-term survival in head and neck cancer. High (18)F-FDG uptake may be useful for identifying patients requiring more aggressive treatment.
PURPOSE: The purpose of this meta-analysis was to evaluate the prognostic value of standard uptake value (SUV) from serial Fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography ((18)F-FDG PET/CT) in patients with head and neck cancer. METHODS: We searched for articles limited to head and neck cancer, dealt with the impact of SUV on survival and published in English. The endpoints were disease-free survival (DFS), overall survival (OS), and local control (LC). Two reviewers extracted data independently. RESULTS: Thirty-five studies were identified; of which, 26 studies involving 1,415 patients met the inclusion criteria. Pooled survival data suggested better DFS, OS, and LC in patients with low SUV of pre-treatment, and the odds ratio (OR) was 0.23, 0.24, and 0.27, respectively. Patients having tumors with low SUV of post-treatment also had significantly better DFS (OR = 0.17) and OS (OR = 0.28) than those with high SUV. CONCLUSIONS: The present meta-analysis showed that (18)F-FDG uptake, as measured by the SUV before treatment and metabolic response after treatment, are valuable for predicting long-term survival in head and neck cancer. High (18)F-FDG uptake may be useful for identifying patients requiring more aggressive treatment.
Authors: Mitchell Machtay; Mona Natwa; Jocelyn Andrel; Terry Hyslop; P Rani Anne; Jororsali Lavarino; Charles M Intenzo; William Keane Journal: Head Neck Date: 2009-02 Impact factor: 3.147
Authors: H Minn; M Lapela; P J Klemi; R Grénman; S Leskinen; P Lindholm; J Bergman; E Eronen; M Haaparanta; H Joensuu Journal: J Nucl Med Date: 1997-12 Impact factor: 10.057
Authors: Byung Hyun Byun; Im Il Na; Gi Jeong Cheon; Hye Jin Kang; Kyeong Min Kim; Seung-Sook Lee; Baek-Yeol Ryoo; Chang Woon Choi; Sang Moo Lim; Sung Hyun Yang Journal: Ann Nucl Med Date: 2008-11-04 Impact factor: 2.668
Authors: Trang H La; Edith J Filion; Brit B Turnbull; Jackie N Chu; Percy Lee; Khoa Nguyen; Peter Maxim; Andy Quon; Edward E Graves; Billy W Loo; Quynh-Thu Le Journal: Int J Radiat Oncol Biol Phys Date: 2009-03-14 Impact factor: 7.038
Authors: Stephen G Spiro; John Buscombe; Gary Cook; Tim Eisen; Fergus Gleeson; Mary O'Brien; Michael D Peake; Nicholas P Rowell; Richard Seymour Journal: Lung Cancer Date: 2007-09-12 Impact factor: 5.705
Authors: K M Greven; D W Williams; J W Keyes; W F McGuirt; N E Watson; M E Randall; M Raben; K R Geisinger; J O Cappellari Journal: Cancer Date: 1994-08-15 Impact factor: 6.860
Authors: Jeffrey M Vainshtein; Matthew E Spector; Jonathan B McHugh; Ka Kit Wong; Heather M Walline; Serena A Byrd; Christine M Komarck; Mohannad Ibrahim; Matthew H Stenmark; Mark E Prince; Carol R Bradford; Gregory T Wolf; Scott McLean; Francis P Worden; Douglas B Chepeha; Thomas Carey; Avraham Eisbruch Journal: Oral Oncol Date: 2014-02-22 Impact factor: 5.337
Authors: J H Rasmussen; B M Fischer; M C Aznar; A E Hansen; I R Vogelius; J Löfgren; F L Andersen; A Loft; A Kjaer; L Højgaard; L Specht Journal: Br J Radiol Date: 2015-01-30 Impact factor: 3.039
Authors: Jon Cacicedo; Arturo Navarro; Olga Del Hoyo; Alfonso Gomez-Iturriaga; Filippo Alongi; Jose A Medina; Olgun Elicin; Andrea Skanjeti; Francesco Giammarile; Pedro Bilbao; Francisco Casquero; Berardino de Bari; Alan Dal Pra Journal: Br J Radiol Date: 2016-08-02 Impact factor: 3.039
Authors: Christophe Van de Wiele; Vibeke Kruse; Peter Smeets; Mike Sathekge; Alex Maes Journal: Eur J Nucl Med Mol Imaging Date: 2012-11-14 Impact factor: 9.236